[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Caribou Biosciences, Inc.\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":54},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":10,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":27,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":42,"lastUpdatePostDateStruct":43,"startDateStruct":46,"completionDateStruct":48,"leadSponsor":50,"locationsCount":53},"100494764",false,"NCT05722418","CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed\u002FRefractory Multiple Myeloma","A Phase 1, Multicenter, Open-Label Study of CB-011, a CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed\u002FRefractory Multiple Myeloma (CaMMouflage Trial)","CaMMouflage","Inclusion Criteria:\n\n1. Documented diagnosis of relapsed\u002Frefractory multiple myeloma (MM) with measurable disease (according to IMWG diagnostic criteria.)\n2. Received at least 3 prior MM treatment lines of therapy which must include a proteasome inhibitor (PI), an immunomodulatory drug (IMiD), and an anti-CD38 monoclonal antibody as part of a prior line of therapy, either in monotherapy or in combination.\n3. Eastern Cooperative Oncology Group performance status grade of 0 or 1.\n4. Adequate hematologic, renal, hepatic, pulmonary, and cardiac function.\n\nExclusion Criteria:\n\n1. Prior treatment with CAR-T cell therapy directed at any target.\n2. Autologous stem cell transplant within the last 6 weeks before lymphodepletion.\n3. Allogeneic stem cell transplant within 6 months before lymphodepletion.\n4. Known active or prior history of CNS involvement.\n5. Stroke or seizure within 6 months of signing ICF.\n6. Seropositive for or history of human immunodeficiency virus.\n7. Vaccinated with live, attenuated vaccine within 4 weeks prior to lymphodepletion.\n8. Hepatitis B infection.\n9. Hepatitis C infection.\n10. Known life-threatening allergies, hypersensitivity, or intolerance to CB-011 or its excipients.","ALL","18 Years",{"count":19,"type":20},50,"ESTIMATED","INTERVENTIONAL",[23],"PHASE1","This is a Phase 1 study to evaluate the safety of CB-011 (the study treatment), an allogeneic chimeric antigen receptor (CAR-T) cell therapy that targets the B cell maturation antigen (BCMA), to determine the best dose of CB-011, and to assess the effectiveness of CB-011 in treating multiple myeloma that has come back (relapsed) or that is no longer responding to other treatment (refractory).",[26],"Relapsed\u002FRefractory Multiple Myeloma",[14,28,29,30,31,32,33,34,35,36,37,38,39,40],"Allogeneic","Multiple Myeloma","Relapse Refractory Multiple Myeloma","CAR-T Cells","BCMA","Cell Therapy","Cellular Immuno-therapy","CB11A","CB-011","CB-011A","CAR-T","Anti BCMA","ALLO CAR T","RECRUITING","2025-09-23",{"date":44,"type":45},"2025-09-25","ACTUAL",{"date":47,"type":45},"2023-02-06",{"date":49,"type":20},"2027-12",{"name":51,"class":52},"Caribou Biosciences, Inc.","INDUSTRY",16,""]